The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs) toward LABA/long-acting muscarinic antagonist (LAMA) FDCs and even LABA/LAMA/ICSFDCs, but current and emerging generics will have a significant impact on this trend. Some branded generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the near future; because cost remains a significant driver, we expect competition from these generics to affect the uptake of both LABA/LAMA and LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease, and the development of novel drug classes continues. QUESTIONS ANSWERED
How will markets react to the launch / uptake of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in the uptake of these generics?
Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?
PRODUCT DESCRIPTION Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.